APOGEE THERAPEUTICS INC

Insider sales by Apogee Therapeutics’ CMO and CEO after AbbVie’s $135‑per‑share acquisition bid show planned exits, not panic, and hint at investor confidence in the deal.

Apogee Therapeutics CEO sells $1.2 M in shares, but keeps 18% stake; insider trades show disciplined strategy, not a bearish signal for investors.

APOGEE insider buys reveal cautious optimism: CMO Carl Dambkowski’s $22.86 purchases, paired with a 10b5‑1 plan, suggest confidence amid a $6.35 B cap and pipeline‑driven upside.

Insider selling continues at Apogee Therapeutics – CFO Jane Henderson’s recent $180 k sale shows routine divestment amid a 32 % monthly rally, not a warning. Stay alert to future clinical milestones for better investment decisions.

Apogee Therapeutics CFO Jane Henderson sells 2,000 shares at $85.00—an insider move reflecting confidence amid a $350 million offer and rising stock.

Insider buy‑the‑dip by Apogee’s CMO Carl Dambkowski: 4,125 shares at $73.08 hints at near‑term upside despite negative earnings, fueling a balanced investor outlook.

Insider CFO sells 2,700 Apogee shares at $70.45/stock, showing disciplined Rule 10b5‑1 trades, not panic—investors can gauge future pipeline upside.